Iqvia Holdings Inc Share Price Nyse
Equities
US74876Y1010
Biotechnology & Medical Research
Sales 2024 * | 15.49B 1,289B | Sales 2025 * | 16.58B 1,380B | Capitalization | 42.12B 3,507B |
---|---|---|---|---|---|
Net income 2024 * | 1.34B 111B | Net income 2025 * | 1.58B 132B | EV / Sales 2024 * | 3.48 x |
Net Debt 2024 * | 11.83B 985B | Net Debt 2025 * | 11.7B 974B | EV / Sales 2025 * | 3.25 x |
P/E ratio 2024 * |
31.5
x | P/E ratio 2025 * |
26.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70% |
Latest transcript on Iqvia Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/16/03 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 01/20/01 |
James Berkshire
COO | Chief Operating Officer | 51 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 03/16/03 |
Colleen Goggins
BRD | Director/Board Member | 68 | 27/17/27 |
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/16/03 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.85B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B | |
-6.26% | 11.58B |